Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris in frontline EATL
NCT03217643Phase 2Completed
- Sponsor
- Institut Imagine
- Start
- Feb 2018
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in enteropathy-associated T-cell lymphoma (EATL), sponsored by Institut Imagine. Started Feb 2018; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
enteropathy-associated T-cell lymphoma (EATL)
Beyond the preview
Go deeper on NCT03217643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217643.